NewGenIVF Announces Reverse Stock Split
NewGenIVF Group Limited (NASDAQ: NIVF), an Asian fertility services provider, has announced a 1-for-10 reverse stock split effective May 5, 2025. The reverse split will reduce outstanding Class A Ordinary Shares from 7,302,819 to approximately 730,282 shares. The company will continue trading under the symbol "NIVF" on the Nasdaq Global Market with a new CUSIP number G0544E121.
No fractional shares will be issued - shareholders entitled to fractional shares will receive one full post-split share instead. All outstanding options, warrants, and convertible securities will be proportionally adjusted by dividing the number of shares by ten, subject to rounding to the nearest whole share.
NewGenIVF Group Limited (NASDAQ: NIVF), un fornitore asiatico di servizi per la fertilit脿, ha annunciato un raggruppamento azionario inverso 1-per-10 con effetto dal 5 maggio 2025. Il raggruppamento ridurr脿 le azioni ordinarie di Classe A in circolazione da 7.302.819 a circa 730.282 azioni. La societ脿 continuer脿 a essere quotata con il simbolo "NIVF" sul Nasdaq Global Market con un nuovo numero CUSIP G0544E121.
Non saranno emesse azioni frazionarie: gli azionisti aventi diritto a frazioni di azioni riceveranno invece una azione intera dopo il raggruppamento. Tutte le opzioni, i warrant e i titoli convertibili in circolazione saranno adeguati proporzionalmente dividendo il numero di azioni per dieci, con arrotondamento all'azione intera pi霉 vicina.
NewGenIVF Group Limited (NASDAQ: NIVF), un proveedor asi谩tico de servicios de fertilidad, ha anunciado una consolidaci贸n inversa de acciones 1 por 10 con efecto a partir del 5 de mayo de 2025. La consolidaci贸n reducir谩 las acciones ordinarias Clase A en circulaci贸n de 7,302,819 a aproximadamente 730,282 acciones. La compa帽铆a continuar谩 cotizando bajo el s铆mbolo "NIVF" en el Nasdaq Global Market con un nuevo n煤mero CUSIP G0544E121.
No se emitir谩n acciones fraccionarias: los accionistas que tengan derecho a acciones fraccionarias recibir谩n una acci贸n completa despu茅s de la consolidaci贸n. Todas las opciones, warrants y valores convertibles en circulaci贸n se ajustar谩n proporcionalmente dividiendo el n煤mero de acciones por diez, con redondeo al n煤mero entero m谩s cercano.
NewGenIVF Group Limited (NASDAQ: NIVF)電� 鞎勳嫓鞎勳潣 靸濎嫕 靹滊箘鞀� 鞝滉车鞐呾泊搿滌劀, 2025雲� 5鞗� 5鞚茧秬韯� 1雽� 10 鞐硲頃� 欤检嫕 攵勴暊鞚� 鞁滍枆頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 鞐硲頃╈溂搿� 旮办〈鞚� 韥措灅鞀� A 氤错喌欤� 7,302,819欤缄皜 鞎� 730,282欤茧 欷勳柎霌媹雼�. 須岇偓電� 雮橃姢雼� 旮�搿滊矊 毵堨紦鞐愳劀 "NIVF" 鞁臣搿� 瓿勳啀 瓯半灅霅橂┌, 靸堧鞖� CUSIP 氩堩樃電� G0544E121鞛呺媹雼�.
攵勴暊 頉� 靻岇垬 欤检嫕鞚� 氚滍枆霅橃 鞎婌溂氅�, 靻岇垬 欤检嫕 甓岆Μ臧� 鞛堧姅 欤检＜電� 雽�鞁� 1欤� 鞝勳泊 欤检嫕鞚� 氚涥矊 霅╇媹雼�. 氇摖 氙戈舶鞝� 鞓奠厴, 鞗岆煱韸�, 鞝勴櫂歃濌秾鞚� 欤检嫕 靾橂ゼ 10鞙茧 雮橂垊鞏� 牍勲 臁办爼霅橂┌, 臧�鞛� 臧�旯岇毚 鞝曥垬搿� 氚橃槵毽茧惄雼堧嫟.
NewGenIVF Group Limited (NASDAQ : NIVF), un fournisseur asiatique de services en fertilit茅, a annonc茅 une division invers茅e d'actions au ratio de 1 pour 10 effective 脿 compter du 5 mai 2025. Cette op茅ration r茅duira les actions ordinaires de Classe A en circulation de 7 302 819 脿 environ 730 282 actions. La soci茅t茅 continuera de n茅gocier sous le symbole "NIVF" sur le Nasdaq Global Market avec un nouveau num茅ro CUSIP G0544E121.
Aucune action fractionnaire ne sera 茅mise 鈥� les actionnaires ayant droit 脿 des fractions d鈥檃ctions recevront une action enti猫re apr猫s la division. Toutes les options, bons de souscription et titres convertibles en circulation seront ajust茅s proportionnellement en divisant le nombre d鈥檃ctions par dix, avec un arrondi 脿 l鈥檃ction enti猫re la plus proche.
NewGenIVF Group Limited (NASDAQ: NIVF), ein asiatischer Anbieter von Fruchtbarkeitsdiensten, hat eine 1-zu-10 Reverse-Aktienzusammenlegung mit Wirkung zum 5. Mai 2025 angek眉ndigt. Die Zusammenlegung reduziert die ausstehenden Stammaktien der Klasse A von 7.302.819 auf etwa 730.282 Aktien. Das Unternehmen wird weiterhin unter dem Symbol "NIVF" am Nasdaq Global Market gehandelt und erh盲lt eine neue CUSIP-Nummer G0544E121.
Bruchst眉cke von Aktien werden nicht ausgegeben 鈥� Aktion盲re, die Anspruch auf Bruchst眉cke haben, erhalten stattdessen je eine ganze Aktie nach der Zusammenlegung. Alle ausstehenden Optionen, Warrants und wandelbaren Wertpapiere werden proportional angepasst, indem die Anzahl der Aktien durch zehn geteilt wird, wobei auf die n盲chste ganze Aktie gerundet wird.
- Potential to maintain Nasdaq listing compliance through higher share price
- Reduced number of shares outstanding could make the stock more attractive to institutional investors
- Reverse splits are often viewed negatively by the market as a sign of company distress
- No fundamental change to company value or market capitalization
Insights
NewGenIVF's 1:10 reverse split reduces share count without changing total company value, a technical adjustment affecting share structure only.
NewGenIVF has announced a 1-for-10 reverse stock split effective May 5, 2025. This technical adjustment will reduce the company's outstanding Class A Ordinary Shares from 7,302,819 to approximately 730,282 shares. For shareholders, this means every 10 shares currently owned will be consolidated into 1 share.
A reverse stock split is a mechanical procedure that consolidates a company's outstanding shares without changing its overall market capitalization (total company value). While each share will represent a larger percentage of ownership, an investor's total percentage ownership in the company remains unchanged.
The company has stated that no fractional shares will be issued. Instead, shareholders entitled to fractional shares will receive one full post-split share, which is slightly beneficial to smaller shareholders.
Additionally, all outstanding options, warrants, and convertible securities will be proportionally adjusted by the same 1:10 ratio, maintaining their relative value and preventing dilution or enrichment of those security holders.
The stock will continue trading under the same ticker symbol "NIVF" but will receive a new CUSIP number (G0544E121), which is a standard procedure for corporate actions of this nature. This identifier change helps market participants track the security correctly after structural modifications.
This corporate action represents a technical adjustment to NewGenIVF's capital structure rather than a fundamental change to its business operations or financial performance.
BANGKOK, May 01, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (鈥淣ewGen鈥� or the 鈥淐ompany鈥�), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it is implementing a reverse stock split of all of the Company's issued and unissued shares at an exchange ratio of one (1) share for ten (10) shares (the 鈥淩everse Stock Split鈥�).
The Company鈥檚 Class A Ordinary Shares will begin trading on the Nasdaq Global Market on a post-Reverse Stock Split basis under the current ticker symbol 鈥淣IVF鈥� at the commencement of trading on May 5, 2025, under the new CUSIP number G0544E121.
The Reverse Stock Split will reduce the number of outstanding Class A Ordinary Shares of the Company from 7,302,819 to approximately 730,282 Class A Ordinary Shares. Every ten (10) outstanding Class A Ordinary Shares will be combined into and automatically become one post-Reverse Stock Split Class A Ordinary Share. No fractional shares will be issued in connection with the Reverse Stock Split. Instead, the Company will issue one full post-Reverse Stock Split Class A Ordinary Share to any shareholder at a participant level who would have been entitled to receive a fractional share as a result of the process.
After the Reverse Stock Split, all options, warrants and other convertible securities of the Company outstanding immediately prior to the Reverse Stock Split will be adjusted by dividing the number of Class A Ordinary Shares into which the options, warrants and other convertible securities are exercisable or convertible by ten (10) in accordance with the terms of the plans, agreements or arrangements governing such options, warrants and other convertible securities and subject to rounding to the nearest whole share.
About NewGen
NewGen is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. With a mission to aid couples and individuals in building families regardless of fertility challenges, NewGen has dedicated itself to creating increased access to infertility treatment and providing comprehensive fertility services for its customers. NewGen鈥檚 management team collectively has over a decade of experience in the fertility industry. NewGen鈥檚 clinics are located in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions, respectively. To learn more, visit . The information contained on, or accessible through, NewGen鈥檚 website is not incorporated by reference into this press release, and you should not consider it a part of this press release.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the 鈥渟afe harbor鈥� provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words 鈥渂elieve,鈥� 鈥減roject,鈥� 鈥渆xpect,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥渋ntend,鈥� 鈥渟trategy,鈥� 鈥渇uture,鈥� 鈥渙pportunity,鈥� 鈥減lan,鈥� 鈥渕ay,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� 鈥渨ill be,鈥� 鈥渨ill continue,鈥� 鈥渨ill likely result,鈥� and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company鈥檚 future commercial operations, business strategy, and financial condition. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company鈥檚 inability to implement its business plans, identify and realize additional opportunities, the Company鈥檚 inability to meet or exceed its financial projections, or changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the Company鈥檚 annual report on Form 20-F and other documents filed or to be filed by the Company with the SEC from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC鈥檚 website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Relations Contact
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
贰尘补颈濒:听
FAQ
What is the reverse stock split ratio for NIVF stock?
How many shares will NIVF have outstanding after the reverse split?
When will NIVF's reverse stock split take effect?
How will NIVF handle fractional shares in the reverse split?
What happens to NIVF options and warrants after the reverse split?
